AIMAIM ImmunoTech

AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen.

As global health agencies monitor emerging infectious disease threats, interest can return quickly to legacy therapeutic platforms with broad antiviral potential. In biotech, especially among smaller names, previously published research can suddenly become highly relevant when the right real-world catalyst emerges. Shares of AIM ImmunoTech Inc. (NYSE American: AIM) are ripping higher in Tuesday trading, climbing after the company highlighted previously published pre-clinical data supporting the potential use of its lead drug candidate, Ampligen, as a prophylactic or early-intervention ...

As global health agencies monitor emerging infectious disease threats, interest can return quickly to legacy therapeutic platforms with broad antiviral potential. In biotech, especially among smaller names, previously published research can suddenly become highly relevant when the right real-world catalyst emerges. Shares of AIM ImmunoTech Inc. (NYSE American: AIM) are ripping higher in Tuesday trading, climbing after the company highlighted previously published pre-clinical data supporting the potential use of its lead drug candidate, Ampligen, as a prophylactic or early-intervention ...

AIM ImmunoTech announced an agreement with certain accredited investors to exercise outstanding warrants for $0.48 per share to raise $4.2 million in gross proceeds.

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

The company said that a patent using its proprietary cancer treatment method was fully approved in Japan.

Here is how AIM ImmunoTech Inc. (AIM) and Cullinan Therapeutics (CGEM) have performed compared to their sector so far this year.

Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

HNST, BROS, AIM, MASI, and CTSH are spotlighted as top-ranked stocks with rising P/E ratios and strong earnings momentum.